Aberdeen Asset Management Plcuk buys $56,765,018 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Aberdeen Asset Management Plcuk scooped up 3,521 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 1,262,848 shares of Abbott Laboratories which is valued at $56,765,018.Abbott Laboratories makes up approximately 0.20% of Aberdeen Asset Management Plcuk’s portfolio.

Other Hedge Funds, Including , Hudock Capital Group boosted its stake in ABT in the latest quarter, The investment management firm added 3 additional shares and now holds a total of 579 shares of Abbott Laboratories which is valued at $26,026. Abbott Laboratories makes up approx 0.01% of Hudock Capital Group’s portfolio.Ramsay Stattman Vela Price boosted its stake in ABT in the latest quarter, The investment management firm added 24,110 additional shares and now holds a total of 137,045 shares of Abbott Laboratories which is valued at $5,984,755. Abbott Laboratories makes up approx 2.88% of Ramsay Stattman Vela Price’s portfolio. Alta Capital Management sold out all of its stake in ABT during the most recent quarter. The investment firm sold 13,589 shares of ABT which is valued $586,637.Hartford Investment Management Co reduced its stake in ABT by selling 8,800 shares or 2.2% in the most recent quarter. The Hedge Fund company now holds 391,458 shares of ABT which is valued at $16,899,242. Abbott Laboratories makes up approx 0.35% of Hartford Investment Management Co’s portfolio. First National Bank Of Mount Dora Trust Investment Services sold out all of its stake in ABT during the most recent quarter. The investment firm sold 4,797 shares of ABT which is valued $204,592.

Abbott Laboratories closed down -0.14 points or -0.31% at $44.81 with 65,83,457 shares getting traded on Thursday. Post opening the session at $45.06, the shares hit an intraday low of $44.78 and an intraday high of $45.09 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.